<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060313214438+01'00'</creation_date><modification_date>D:20070831105644+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_20.pdf</pdf_file></head><body><section><header>i commission of the european communities  brussels, 25/05/2000 c(2000) 1407</header></section><section><header>commission decision of 25/05/2000 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;pegintron - peginterferon alfa-2b&quot; 
 only the french and the dutch texts are authentic.</header><p>ii</p></section><section><header>commission decision of 25/05/2000 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;pegintron - peginterferon alfa-2b&quot; 
 only the french and the dutch texts are authentic.</header><p>the commission of the european communities,</p><p>having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, and in particular article 10(1) and (2) thereof,</p><p>having regard to the application submitted by sp europe, on 26 march 1999, under 
 article 4(1) of regulation (eec) no 2309/93, concerning the medicinal product, 
 &quot;pegintron - peginterferon alfa-2b&quot;, 
 having regard to the opinion of 17 february 2000 of the european agency for the 
 evaluation of medicinal products, formulated by the committee for proprietary 
 medicinal products,</p><p>
 whereas:</p><p>
 (1)</p><p>the medicinal product, &quot;pegintron - peginterferon alfa-2b&quot;, complies with the 
 requirements of council directives 65/65/eec
 2, 75/318/eec3 and 75/319/eec4, as last amended by directive 93/39/eec
 5;</p><p>
 1 oj no l 214, 24. 8. 1993, p. 1. 2 oj no 22, 9.2.1965, p. 369/65. 3 oj no l 147, 9.6.1975, p. 1. 4 oj no l 147, 9.6.1975, p. 13. 5 oj no l 214, 24.8.1993, p. 22.</p><p> iii(2)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 has adopted this decision:</p><p>
 article 1</p><p>the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product, &quot;pegintron - peginterferon alfa-2b&quot; 
 whose characteristics are summarized in annex i hereto. this medicinal product shall be 
 entered in the community register of medicinal products under the numbers:</p><p>
 eu/1/00/131/001 
 pegintron - 50 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule - subcutaneous use 
 eu/1/00/131/002 
 pegintron - 50 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule + 1 injection set - subcutaneous use 
 eu/1/00/131/003 
 pegintron - 50 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules - subcutaneous use 
 eu/1/00/131/004 
 pegintron - 50 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules + 4 injection sets - subcutaneous use 
 eu/1/00/131/005 
 pegintron - 50 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 6 vials + 
 6 ampoules - subcutaneous use 
 eu/1/00/131/006 
 pegintron - 80 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule - subcutaneous use 
 eu/1/00/131/007 
 pegintron - 80 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule + 1 injection set - subcutaneous use 
 eu/1/00/131/008 
 pegintron - 80 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules - subcutaneous use 
 eu/1/00/131/009 
 pegintron - 80 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules + 4 injection sets - subcutaneous use</p><p> iveu/1/00/131/010 
 pegintron - 80 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 6 vials + 
 6 ampoules - subcutaneous use 
 eu/1/00/131/011 
 pegintron - 100 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule - subcutaneous use 
 eu/1/00/131/012 
 pegintron - 100 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule + 1 injection set - subcutaneous use 
 eu/1/00/131/013 
 pegintron - 100 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules - subcutaneous use 
 eu/1/00/131/014 
 pegintron - 100 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules + 4 injection sets - subcutaneous use 
 eu/1/00/131/015 
 pegintron - 100 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 6 vials + 
 6 ampoules - subcutaneous use 
 eu/1/00/131/016 
 pegintron - 120 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule - subcutaneous use 
 eu/1/00/131/017 
 pegintron - 120 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule + 1 injection set - subcutaneous use 
 eu/1/00/131/018 
 pegintron - 120 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules - subcutaneous use 
 eu/1/00/131/019 
 pegintron - 120 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules + 4 injection sets - subcutaneous use 
 eu/1/00/131/020 
 pegintron - 120 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 6 vials + 
 6 ampoules - subcutaneous use 
 eu/1/00/131/021 
 pegintron - 150 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule - subcutaneous use 
 eu/1/00/131/022 
 pegintron - 150 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 1 vial + 1 
 ampoule + 1 injection set - subcutaneous use</p><p> veu/1/00/131/023 
 pegintron - 150 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules - subcutaneous use 
 eu/1/00/131/024 
 pegintron - 150 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 4 vials + 
 4 ampoules + 4 injection sets - subcutaneous use 
 eu/1/00/131/025 
 pegintron - 150 micrograms - powder and solvent for solution for 
 injection - powder: vial (glass); solvent: ampoule (glass) - 6 vials + 
 6 ampoules - subcutaneous use</p><p>
 article 2</p><p>the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and/or importation, control and issue referred to in annex ii.</p><p>
 article 3</p><p>the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii.</p><p>
 article 4</p><p>the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in 
 article 13(1) of regulation (eec) no 2309/93.</p><p>
 article 5</p><p>this decision is addressed to sp europe, rue de stalle, 73, 1180 bruxelles, belgique.</p><p>done at brussels, 25/05/2000 
 for the commission erkki liikanen 
 member of the commision</p></section></body></xml>